Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Reports Full-Year 2018 Financial Results
March 28, 2019 13:00 ET | Quantum Genomics
A 2018 fiscal year marked by significant progress in the following research programs:-- Arterial hypertension: highly significant efficacy of firibastat demonstrated in completed Phase IIb trial,...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Announces Positive Results from New Preclinical Studies on Firibastat
March 20, 2019 13:00 ET | Quantum Genomics
PARIS and NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company announces positive results from preclinical reproductive...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Completes Enrollment in Its Pharmacokinetic Clinical Study of Firibastat
February 25, 2019 12:00 ET | Quantum Genomics
PARIS and NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Announces the Publication of Two Scientific Articles Confirming the Efficacy of Firibastat for Heart Failure
February 06, 2019 12:00 ET | Quantum Genomics
PARIS and NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Presents its 2019 Corporate Action Plan
January 31, 2019 13:12 ET | Quantum Genomics
PARIS, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly...
Quantum Genomics has joined the Pass French Tech program
February 23, 2017 12:00 ET | Quantum Genomics
PARIS and NEW YORK, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical...
Quantum Genomics announces 2016 first-half financial results and first nine months business update
October 13, 2016 12:00 ET | Quantum Genomics
Sound balance sheet: €13.2 M cash and no financial debt at 30 June18-month financial visibilityPARIS and NEW YORK, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 -...
Quantum Genomics reports positive top-line results from Phase IIa trial of QGC001 in hypertension
September 29, 2016 11:45 ET | Quantum Genomics
Results enable initiation of additional hypertension studies for lead candidateCompany to conduct a U.S. Phase II trial in targeted patient population based on FDA advice PARIS and NEW YORK, Sept. ...
Quantum Genomics Announces Conference Call to Review Top-line Results from Phase IIa Study of QGC001 in Hypertension
September 22, 2016 12:00 ET | Quantum Genomics
PARIS and NEW YORK, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet...
Quantum Genomics to announce Phase IIa clinical trial results for high blood pressure on September 29, 2016
September 12, 2016 12:00 ET | Quantum Genomics
PARIS and NEW YORK, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet...